David Barthel - 08 Feb 2022 Form 4 Insider Report for MARIZYME INC (MRZM)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MRZM
Reported as of: 08 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2022, 16:17:25 UTC
Prior SEC filing: 06 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ David Barthel

Key filing fact

David Barthel filed Form 4 for MARIZYME INC (MRZM) on 09 Feb 2022.

Key facts

This page summarizes David Barthel's Form 4 filing for MARIZYME INC (MRZM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Feb 2022, 16:17.

Change

Previous filing in this sequence was filed on 06 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRZM transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -400,000
Change %: -100%
Price
Shares after: 0
Date: 08 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $2.25
Footnotes: F1

MRZM transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +400,000
Change %
Price
Shares after: 400,000
Date: 08 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $1.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted as of October 31, 2021. The option vested as to 40,000 shares upon the original option's grant date of October 31, 2021 pursuant to the Executive Employment Agreement between the reporting person and the issuer dated as of October 31, 2021, as amended on February 8, 2022. The balance of 360,000 shares vest on a quarterly basis over the three (3) year period following October 31, 2021 in equal installments.